T1	Condition 40 57	Myasthenia Gravis
T2	Condition-Name 40 57	Myasthenia Gravis
E1	Condition:T1 Name:T2 Duration:E4
T3	Condition 357 381	meningococcal infections
T4	Condition-Name 357 381	meningococcal infections
E3	Condition:T3 Name:T4 Temporality:E11
T5	Condition 484 493	infection
T6	Condition-Name 484 493	infection
E5	Condition:T5 Name:T6
T7	Procedure 759 769	thymectomy
T8	Procedure-Name 759 769	thymectomy
E7	Procedure:T7 Name:T8 Temporality:E48 Temporality2:E49
T9	Procedure 996 1011	plasma exchange
T10	Procedure-Name 996 1011	plasma exchange
E9	Procedure:T9 Name:T10 Temporality:E14
T11	Eq-Operator 289 290	≥
A1	Eq-Operator-Value T11 GTEQ
T12	Eq-Operator 382 388	within
A2	Eq-Operator-Value T12 LTEQ
T13	Eq-Operator 715 716	≥
A3	Eq-Operator-Value T13 GTEQ
T14	Eq-Operator 770 776	within
A4	Eq-Operator-Value T14 LTEQ
T16	Eq-Operator 947 953	within
A6	Eq-Operator-Value T16 LTEQ
T17	Eq-Operator 1012 1018	within
A7	Eq-Operator-Value T17 LTEQ
T18	Eq-Operator 1071 1077	within
A8	Eq-Operator-Value T18 LTEQ
T19	Eq-Temporal-Unit 69 75	months
A9	Eq-Temporal-Unit-Value T19 month
T20	Eq-Temporal-Unit 81 85	days
A10	Eq-Temporal-Unit-Value T20 day
T21	Eq-Temporal-Unit 391 396	years
A11	Eq-Temporal-Unit-Value T21 year
T22	Eq-Temporal-Unit 719 724	years
A12	Eq-Temporal-Unit-Value T22 year
T23	Eq-Temporal-Unit 784 790	months
A13	Eq-Temporal-Unit-Value T23 month
T24	Eq-Temporal-Unit 956 961	weeks
A14	Eq-Temporal-Unit-Value T24 week
T25	Eq-Temporal-Unit 1021 1026	weeks
A15	Eq-Temporal-Unit-Value T25 week
T26	Eq-Temporal-Unit 1080 1086	months
A16	Eq-Temporal-Unit-Value T26 month
T27	Eq-Value 67 68	6
T28	Eq-Value 291 292	6
T30	Eq-Value 389 390	3
T31	Eq-Value 717 718	5
T32	Eq-Value 781 783	12
T33	Eq-Value 954 955	4
T34	Eq-Value 1019 1020	4
T35	Eq-Value 1078 1079	6
T36	Eq-Comparison 289 292	≥ 6
E10	Eq-Comparison:T36 Operator:T11 Value:T28
T37	Eq-Comparison 382 396	within 3 years
E11	Eq-Comparison:T37 Operator:T12 Temporal-Unit:T21 Value:T30
T38	Eq-Comparison 715 724	≥ 5 years
E12	Eq-Comparison:T38 Operator:T13 Temporal-Unit:T22 Value:T31
T39	Eq-Comparison 947 961	within 4 weeks
E13	Eq-Comparison:T39 Operator:T16 Temporal-Unit:T24 Value:T33
T40	Eq-Comparison 1012 1026	within 4 weeks
E14	Eq-Comparison:T40 Operator:T17 Temporal-Unit:T25 Value:T34
T41	Eq-Comparison 1071 1086	within 6 months
E15	Eq-Comparison:T41 Operator:T18 Temporal-Unit:T26 Value:T35
T42	Study 112 121	Screening
E2	Study:T42 
T43	Eq-Comparison 58 75	at least 6 months
E4	Eq-Comparison:T43 Operator:T44 Temporal-Unit:T19 Value:T27
T44	Eq-Operator 58 66	at least
A17	Eq-Operator-Value T44 GTEQ
T45	Eq-Comparison 77 85	180 days
E6	Eq-Comparison:T45 Value:T46 Temporal-Unit:T20
T46	Eq-Value 77 80	180
R1	Equivalent-To Arg1:E6 Arg2:E4	
T47	Temporal-Connection 87 92	prior
E8	Temporal-Connection:T47 Arg:E4 Arg2:E2
A18	Temporal-Connection-Type-Value E8 before
T48	Condition 168 231	Myasthenia Gravis Foundation of America Clinical Classification
E16	Condition:T48 Name:T49 Stage:E17
T49	Condition-Name 168 231	Myasthenia Gravis Foundation of America Clinical Classification
T50	Eq-Comparison 232 246	Class II to IV
E17	Eq-Comparison:T50 Unit:T51 Value:T52 Value2:T54 Operator:T53
T51	Eq-Unit 232 237	Class
T52	Eq-Value 238 240	II
T53	Eq-Operator 241 243	to
A19	Eq-Operator-Value T53 BETWEEN
T54	Eq-Value 244 246	IV
T55	Study 250 259	screening
E18	Study:T55 
T56	Temporal-Connection 247 249	at
E19	Temporal-Connection:T56 Arg:E16 Arg2:E18
A20	Temporal-Connection-Type-Value E19 during
T57	Observation 266 272	MG-ADL
E20	Observation:T57 Name:T58 Eq-Comparison:E10
T58	Observation-Name 266 272	MG-ADL
A21	Observation-Type-Value T58 clinical-score
T59	Study 296 305	screening
E21	Study:T59 
T29	Temporal-Connection 293 295	at
E22	Temporal-Connection:T29 Arg:E20 Arg2:E21
A22	Temporal-Connection-Type-Value E22 during
T60	Immunization 338 348	Vaccinated
E23	Immunization:T60 
R2	Treatment-For Arg1:E23 Arg2:E3	
T61	Risk 462 466	risk
E24	Risk:T61 Risk-For:E5
T62	Organism 495 509	N meningitidis
E25	Organism:T62 Name:T63
T63	Organism-Name 495 509	N meningitidis
T64	Study 437 442	study
E26	Study:T64 Study-Of:E27
T65	Drug 443 447	drug
E27	Drug:T65 
R4	Treatment-For Arg1:E27 Arg2:E5	
T66	Temporal-Connection 397 405	prior to
E28	Temporal-Connection:T66 Arg:E11
A23	Temporal-Connection-Type-Value E28 before
T67	Temporal-Connection 410 412	at
E29	Temporal-Connection:T67 Arg:E26
A24	Temporal-Connection-Type-Value E29 during
T68	Or 407 409	or
E30	Or:T68 Arg:E28 Arg2:E29
T69	Condition 532 550	Medical Conditions
E31	Condition:T69 
T70	Condition 580 587	thymoma
E32	Condition:T70 Name:T71 Temporality:E33
T71	Condition-Name 580 587	thymoma
T72	Eq-Comparison 560 566	active
E33	Eq-Comparison:T72 Temporal-Period:T73
T73	Eq-Temporal-Period 560 566	active
A25	Eq-Temporal-Period-Value T73 present
T76	Or 567 569	or
E36	Or:T76 Arg:E33 Arg2:E34
T77	Eq-Comparison 589 596	History
E37	Eq-Comparison:T77 Temporal-Period:T78
T78	Eq-Temporal-Period 589 596	History
A26	Eq-Temporal-Period-Value T78 past
T79	Condition 600 616	thymic carcinoma
E38	Condition:T79 Name:T80 Temporality:E37
T80	Condition-Name 600 616	thymic carcinoma
T81	Condition 620 637	thymic malignancy
E39	Condition:T81 Name:T82
T82	Condition-Name 620 637	thymic malignancy
T83	Or 617 619	or
E40	Or:T83 Arg:E38 Arg2:E39
T84	Study 732 741	screening
E41	Study:T84 
T85	Temporal-Connection 725 731	before
E42	Temporal-Connection:T85 Arg:E12 Arg2:E41
A27	Temporal-Connection-Type-Value E42 before
T86	Procedure 670 679	treatment
E43	Procedure:T86 
T87	Coreference 700 710	recurrence
E44	Coreference:T87 Refers-To:E39 Temporality:E12
T88	Negation 685 687	no
E45	Negation:T88 Negates:E44
R6	Treatment-For Arg1:E43 Arg2:E39	
T89	And 680 684	with
E46	And:T89 Arg:E43 Arg2:E45
T90	Exception 638 644	unless
E47	Exception:T90 From:E39 Except:E43
T91	Eq-Comparison 748 755	History
E48	Eq-Comparison:T91 Temporal-Period:T92
T92	Eq-Temporal-Period 748 755	History
A28	Eq-Temporal-Period-Value T92 past
T93	Eq-Comparison 770 790	within the 12 months
E49	Eq-Comparison:T93 Operator:T14 Temporal-Unit:T23 Value:T32
T94	Study 800 809	screening
E50	Study:T94 
T95	Temporal-Connection 791 796	prior
E51	Temporal-Connection:T95 Arg:E49 Arg2:E50
A29	Temporal-Connection-Type-Value E51 before
T96	Condition 842 851	infection
E52	Condition:T96 Name:T97 Temporality:E53
T97	Condition-Name 842 851	infection
T98	Eq-Comparison 816 823	History
E53	Eq-Comparison:T98 Temporal-Period:T99
T99	Eq-Temporal-Period 816 823	History
A30	Eq-Temporal-Period-Value T99 past
T15	Drug 929 946	IV immunoglobulin
E54	Drug:T15 Name:T100 Temporality:E13
T100	Drug-Name 929 946	IV immunoglobulin
T101	Study 965 978	randomization
E55	Study:T101 
T102	Temporal-Connection 962 964	of
E56	Temporal-Connection:T102 Arg:E13 Arg2:E55
A5	Temporal-Connection-Type-Value E56 before
T103	Study 1030 1043	randomization
E57	Study:T103 
T104	Temporal-Connection 1027 1029	of
E58	Temporal-Connection:T104 Arg:E14 Arg2:E57
A31	Temporal-Connection-Type-Value E58 before
T105	Drug 1061 1070	rituximab
E59	Drug:T105 Name:T106 Temporality:E15
T106	Drug-Name 1061 1070	rituximab
T107	Study 1090 1099	screening
E60	Study:T107 
T108	Temporal-Connection 1087 1089	of
E61	Temporal-Connection:T108 Arg:E15 Arg2:E60
A32	Temporal-Connection-Type-Value E61 before
T109	Drug 1160 1181	complement inhibitors
E62	Drug:T109 Name:T110
T110	Drug-Name 1160 1181	complement inhibitors
T111	Drug 1196 1206	eculizumab
E63	Drug:T111 Name:T112
T112	Drug-Name 1196 1206	eculizumab
R7	Example-Of Arg1:E63 Arg2:E62	
T113	Eq-Comparison 1136 1144	previous
E64	Eq-Comparison:T113 Temporal-Period:T114
T114	Eq-Temporal-Period 1136 1144	previous
A33	Eq-Temporal-Period-Value T114 past
T115	Procedure 1145 1154	treatment
E65	Procedure:T115 Temporality:E64
R8	Using Arg1:E65 Arg2:E62
T74	Negation 570 579	untreated
E34	Negation:T74 Negates:E67
T75	Organism 827 841	N meningitidis
E35	Organism:T75 Name:T116
T116	Organism-Name 827 841	N meningitidis
R3	Caused-By Arg1:E5 Arg2:E25	
T117	Modifier 470 483	meningococcal
E66	Modifier:T117 Modifies:T6
R9	Caused-By Arg1:E52 Arg2:E35	
T118	Procedure 570 579	untreated
E67	Procedure:T118 
R5	Treatment-For Arg1:E67 Arg2:E32	
